{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-24-000044","form_type":"8-K/A","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.366083+00:00","generated_at":"2026-05-30T02:03:04.372990+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed","bullets":["Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.","Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.","Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.","Higher interest expense drove GAAP net loss and lower adjusted EPS."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-24-000044","json":"https://secwatch.observer/filing/0001723128-24-000044.json","markdown":"https://secwatch.observer/filing/0001723128-24-000044.md","text":"https://secwatch.observer/filing/0001723128-24-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/0001723128-24-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312824000044/amrx-20241108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:03:04.372990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}